A Phase 3 interventional study of Cetuximab and Panitumumab in Metastatic Colorectal Cancer, sponsored by Amgen. Completed at 152 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 6th largest by enrollment of the 88 interventional ones that give a count, is one of 10 that started in 2010, is one of 14 in phase 3, and was the 35th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,010 is above the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 4th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2010, is one of 10 in phase 3, and was the 24th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cetuximab 400 mg/m\^2 as an initial dose, followed by 250 mg/m\^2 intravenously (IV) every 7 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
Drug: Cetuximab
Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
Drug: Panitumumab
Administered by intravenous infusion
Also known as: Erbitux
Administered by intravenous infusion
Also known as: Vectibix
Overall Survival
Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Progression-free Survival
Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Objective Response
Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Duration of Response
Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Time to Response
Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Time to Treatment Failure
Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.
Time frame: From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.
Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The VAS asks respondents to rate their present health status on a 0 - 100 scale, with 0 labeled as "Worst imaginable health state" and 100 labeled as "Best imaginable health state." The VAS score is determined by observing the point at which the participant's hand drawn line intersects the scale.
Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Change From Baseline in NCCN FCSI Physical Well-being Scale Score
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Change From Baseline in NCCN FCSI Functional Well-being Scale Score
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
Time frame: From Study Day 1 through the last day of treatment or disease progression, up to Week 85.
Number of Participants With Adverse Events (AEs)
Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.
Time frame: From the day of the first dose of study therapy through 30 days since the last dose. Maximum time on study treatment was 130 weeks.
First patient enrolled on 2nd February 2010 and last patient enrolled 19 July 2012. Results are reported as of the data cut-off date of 5 February 2013.
| Milestone | Cetuximab | Panitumumab |
|---|---|---|
| Started | 504 | 506 |
| Received treatment | 500 | 499 |
| Completed | 78 | 85 |
| Not completed | 426 | 421 |
| Withdrew: Ineligibility determined | 2 | 0 |
| Withdrew: Withdrawal by subject | 19 | 20 |
| Withdrew: Lost to follow-up | 14 | 17 |
| Withdrew: Death | 391 | 384 |
Overall survival is the time from the date of randomization until the date of death. Participants who had not died by the analysis data cut-off date were censored at their last contact date.
| months | Cetuximab | Panitumumab |
|---|---|---|
| Overall Survival | 10.0 (9.3 to 11.0) | 10.4 (9.4 to 11.6) |
Progression free survival (PFS) is the time from the date of randomization to the date of disease progression per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death. Participants alive and not meeting criteria for progression by the analysis data cut-off date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started (the sum must also demonstrate an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or any new lesions.
| months | Cetuximab | Panitumumab |
|---|---|---|
| Progression-free Survival | 4.4 (3.2 to 4.8) | 4.1 (3.2 to 4.8) |
Objective response is either a complete response (CR) or partial response (PR) per RECIST version 1.1. All participants that did not meet the criteria for an objective response by the analysis cut-off date were considered non-responders. CR: Disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm, and disappearance of all non-target lesions, and no new lesions. PR: Disappearance of all target lesions, persistence of one or more non-target lesions not qualifying for either CR or progressive disease, or, at least a 30% decrease in the sum of diameters of target lesions with no unequivocal progression of existing non-target lesions and no new lesions.
| percentage of participants | Cetuximab | Panitumumab |
|---|---|---|
| Objective Response | 19.79 (16.34 to 23.62) | 22.02 (18.41 to 25.97) |
Duration of response (DOR), calculated only for those participants with an objective response, is the time from first objective response to disease progression per the RECIST v1.1 or death. Participants not meeting criteria for progression or who died by the analysis data cutoff date were censored at their last evaluable disease assessment date.
| months | Cetuximab | Panitumumab |
|---|---|---|
| Duration of Response | 5.4 (3.8 to 5.5) | 3.8 (3.7 to 4.8) |
Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.
| months | Cetuximab | Panitumumab |
|---|---|---|
| Time to Response | 2.6 (1.2 to 3.1) | 1.5 (1.2 to 3.0) |
Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.
| months | Cetuximab | Panitumumab |
|---|---|---|
| Time to Treatment Failure | 3.3 (3.2 to 3.9) | 3.4 (3.2 to 4.6) |
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.
| scores on a scale | Cetuximab | Panitumumab |
|---|---|---|
| Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score | -0.0341 (-0.0806 to 0.0123) | -0.0216 (-0.0691 to 0.0260) |
The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The VAS asks respondents to rate their present health status on a 0 - 100 scale, with 0 labeled as "Worst imaginable health state" and 100 labeled as "Best imaginable health state." The VAS score is determined by observing the point at which the participant's hand drawn line intersects the scale.
| scores on a scale | Cetuximab | Panitumumab |
|---|---|---|
| Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS) | 3.9782 (0.8842 to 7.0722) | 2.3037 (-0.8532 to 5.4605) |
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
| scores on a scale | Cetuximab | Panitumumab |
|---|---|---|
| Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score | 2.0101 (-1.1477 to 5.1679) | 3.0473 (-0.1782 to 6.2728) |
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
| scores on a scale | Cetuximab | Panitumumab |
|---|---|---|
| Change From Baseline in NCCN FCSI Physical Well-being Scale Score | 1.8778 (-1.5524 to 5.3080) | 2.4614 (-1.0442 to 5.9670) |
The FCSI consists of 9 questions comprising the most important symptoms associated with colorectal cancer, including energy, pain, weight, diarrhea, nausea, swelling or cramps in the stomach area, appetite, ability to enjoy life, and overall quality of life. The 9 questions are combined in three algorithms to provide information for 3 domains: colorectal cancer symptoms, physical well-being, and functional well-being. Each of the 9 items are scored from "0" to "4" representing "Not at All" through to "Very Much True". The raw score for all items is transformed to a 0-100 scale, and the average for each of the 3 subscales is calculated; high scores illustrate an improved state (e.g. able to enjoy life more).
| scores on a scale | Cetuximab | Panitumumab |
|---|---|---|
| Change From Baseline in NCCN FCSI Functional Well-being Scale Score | 1.3567 (-4.1564 to 6.8697) | 1.1569 (-4.4887 to 6.8025) |
Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.
| participants | Cetuximab | Panitumumab |
|---|---|---|
| Any adverse event (AE) | 494 | 485 |
| Serious adverse events | 169 | 151 |
| Leading to discontinuation of study drug | 61 | 69 |
| Any treatment-related adverse event (TRAE) | 459 | 437 |
| Treatment-related serious adverse event | 22 | 25 |
| TRAE leading to discontinuation of study drug | 15 | 14 |
Collected over Median time was 117 days for panitumumab arm and 123 days for cetuximab arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab | — | 169/503 (33.6%) | 474/503 (94.2%) |
| Panitumumab | — | 151/496 (30.4%) | 459/496 (92.5%) |
| Event | Cetuximab | Panitumumab |
|---|---|---|
| Colorectal cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 14/503 | 7/496 |
| Abdominal painGastrointestinal disorders | 13/503 | 10/496 |
| Intestinal obstructionGastrointestinal disorders | 8/503 | 12/496 |
| VomitingGastrointestinal disorders | 5/503 | 12/496 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/503 | 7/496 |
| Urinary tract infectionInfections and infestations | 7/503 | 9/496 |
| DiarrhoeaGastrointestinal disorders | 8/503 | 6/496 |
| PyrexiaGeneral disorders | 8/503 | 3/496 |
| PneumoniaInfections and infestations | 7/503 | 2/496 |
| AnaemiaBlood and lymphatic system disorders | 3/503 | 6/496 |
| Event | Cetuximab | Panitumumab |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 257/503 | 249/496 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 136/503 | 138/496 |
| HypomagnesaemiaMetabolism and nutrition disorders | 89/503 | 134/496 |
| DiarrhoeaGastrointestinal disorders | 87/503 | 88/496 |
| PruritusSkin and subcutaneous tissue disorders | 88/503 | 83/496 |
| FatigueGeneral disorders | 85/503 | 72/496 |
| Dry skinSkin and subcutaneous tissue disorders | 79/503 | 83/496 |
| Decreased appetiteMetabolism and nutrition disorders | 77/503 | 69/496 |
| ParonychiaInfections and infestations | 75/503 | 58/496 |
| Abdominal painGastrointestinal disorders | 74/503 | 52/496 |
| Age, Continuous(years) | Cetuximab | Panitumumab | Total |
|---|---|---|---|
| Mean | 60.2 ± 11.2 | 59.6 ± 10.9 | 59.9 ± 11.1 |
| Sex: Female, Male(Participants) | Cetuximab | Panitumumab | Total |
|---|---|---|---|
| Female | 183 | 187 | 370 |
| Male | 321 | 319 | 640 |
| Race/Ethnicity, Customized(participants) | Cetuximab | Panitumumab | Total |
|---|---|---|---|
| Asian | 230 | 225 | 455 |
| Black or African American | 4 | 2 | 6 |
| Hispanic or Latino | 7 | 6 | 13 |
| Japanese | 0 | 1 | 1 |
| Other | 3 | 2 | 5 |
| White or Caucasian | 260 | 270 | 530 |
| Geographic region(participants) | Cetuximab | Panitumumab | Total |
|---|---|---|---|
| North America, Western Europe and Australia | 158 | 158 | 316 |
| Rest of World | 346 | 348 | 694 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | Cetuximab | Panitumumab | Total |
|---|---|---|---|
| Grade 0 | 165 | 155 | 320 |
| Grade 1 | 299 | 309 | 608 |
| Grade 2 | 40 | 42 | 82 |
Showing the first 100 of 152 sites across 29 countries. Choose a country and city above to see the rest.
Ran from Feb 2010 to primary completion in Feb 2013, 36 months.
Results were first posted in Mar 2014, 1 year 1 month after primary completion.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 36 months is below that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panitumumab